Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT

Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT

Abstract Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment option in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). DIRECT (Dose Intensity RElative to Ce...

Full description

Bibliographic Details
Main Authors: Joël Guigay, Emmanuel Chamorey, Gautier Lefebvre, Maciej Rotarski, Jean‐Philippe Wagner, Emmanuel Blot, Marc Alfonsi, Audrey Seronde, Jeltje Schulten, Frédéric Peyrade, Christophe Le Tourneau
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Cancer Reports
Subjects:
5‐fluorouracil
carboplatin
cetuximab
cisplatin
head and neck neoplasms
palliative care
Online Access:https://doi.org/10.1002/cnr2.1467

Internet

https://doi.org/10.1002/cnr2.1467

Similar Items